Showing 1421-1430 of 2910 results for "".
- Explanation for the New Brunswick Mystery Illness Proposed in New Articlehttps://practicalneurology.com/news/explanation-for-the-new-brunswick-mystery-illness-proposed-in-new-article/2474615/The cluster of cases initially identified as the New Brunswick neurological syndrome of unknown cause (NSUC) and thought to constitute a novel neurologic disorder is likely to be a combination of well-known and misdiagnosed disorders, according to results of a cross-sectional study published in J
- New Podcast on COVID-19 Pandemic for People With Parkinson Diseasehttps://practicalneurology.com/news/new-podcast-on-covid-19-pandemic-for-people-with-parkinson-disease/2469251/A limited podcast series by the Michael J. Fox Foundation (MJFF) for Parkinson's Research will begin Wednesday, May 6, 2020. The series is designed to help individuals with Parkinson disease (PD) and their caregivers and partners navigate their way through the COVID-19 pandemic.
- New Guidelines Issued for Gene Therapy Treatment in Duchenne Muscular Dystrophyhttps://practicalneurology.com/news/new-guidelines-issued-for-gene-therapy-treatment-in-duchenne-muscular-dystrophy/2483121/The Muscular Dystrophy Association (MDA) and Parent Project Muscular Dystrophy (PPMD) have jointly published consensus guidelines on the safe and equitable administration of gene therapy for Duchenne muscular dystrophy (DMD) in Neuromuscular Disorders. The recommendations provide neurolo
- Diagnosis and Care Recommendations for Limb-Girdle Muscle Dystrophy 2I/R9 Presentedhttps://practicalneurology.com/news/diagnosis-and-care-recommendations-for-limb-girdle-muscle-dystrophy-2ir9-presented/2473813/Draft standard of care (SoC) guidelines for the diagnosis and management of people with limb-girdle muscle dystrophy 2I/R9 (LGMDR9) were presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. According to the presenters of the draft SoC, the guidelines ar
- Over $500,000 Awarded for ALS and Mitochondrial Myopathies Researchhttps://practicalneurology.com/news/over-500000-awarded-for-als-and-mitochondrial-myopathies-research/2470938/The Muscular Dystrophy Association (MDA; Chicago, IL) has partnered with the French Muscular Dystrophy Association (AFM-Téléthon; Evry, France) to award a total of $510,000 in grant funding across 2 research projects. The grant funding is intended to accelerate the development of tr
- Muscular Dystrophy Association Launches Initiative to Support the Development of Treatments for Ultra-Rare Neuromuscular Diseaseshttps://practicalneurology.com/news/muscular-dystrophy-association-launches-initiative-to-support-the-development-of-treatments-for-ultra-rare-neuromuscular-diseases/2470571/The Muscular Dystrophy Association (MDA) announced the launch of the MDA Kickstart Program, an initiative to advance the development of treatments for ultra-rare neuromuscular diseases. The first project under the MDA Kickstart Program will focus on the development of a gene therapy for a rare fo
- Muscular Dystrophy Association Applauds Landmark Proposal on Accessible Air Travelhttps://practicalneurology.com/news/muscular-dystrophy-association-applauds-landmark-proposal-on-accessible-air-travel/2470417/The Muscular Dystrophy Association (MDA) celebrates a significant milestone in air travel accessibility for individuals with disabilities related to a proposal aimed at enhancing the safety, rights, and dignity of air travelers with disabilities made by the Biden Administration and the US Departm
- Muscular Dystrophy Association Announces the Start of 30 Days of Strength Campaignhttps://practicalneurology.com/news/mda-announces-the-start-of-30-days-of-strength-campaign/2470289/The Muscular Dystrophy Association (MDA) has announced the start of its 30 Days of Strength campaign for September, which is National Muscular Dystrophy Awareness Month. Throughout the month, the MDA will collaborate with influencers and community leaders, including Nyheim Hines, running back for
- VA Will Cover Lecanemab for Alzheimer Diseasehttps://practicalneurology.com/news/va-will-cover-lecanemab-for-alzheimer-disease/2470141/The Veterans Health Administration (VHA)—the division of the US D
- Ribitol Decreased Muscle Breakdown and Improved Function in Limb-Girdle Muscular Dystrophyhttps://practicalneurology.com/news/ribitol-decreased-muscle-breakdown-and-improved-function-in-limb-girdle-muscular-dystrophy/2470048/In a phase 2 study, individuals treated with ribitol (BBP-418; BridgeBio Pharma, Palo Alto, CA) for limb girdle muscular dystrophy type 2i (LGMD2i) for 12 months had a mean 75% reduction in creatine kinase (CK) levels—a marker of muscle degeneration. A mean 0.95-point improvement from basel